Greece has followed a policy which “proves that we want a stable investment environment in which pharmaceutical companies can invest,” Development and Investment Minister Adonis Georgiadis said on Monday at the opening of the Delphi Economic Forum VI at Zappeion Hall.
Speaking at the session on “Pharmaceutical innovation: investment standing the test of time”, Georgiadis said the government is seeking “policies that will benefit from the broadest possible political consensus in the country.”
One of those actions, put in place by the previous government and continued, is a task force that is examining the idea of institutionalizing an investment clawback, as he called it.
“I have no reason to hide what our predecessors did, and I like to show that we have continuity as a state and that despite the acute conflicts we can sometimes have and a clash of ideas, we are still compatriots and fight for the common good. ,” he said.
“In 2019, we introduced a law with the Ministry of Health for the recovery of investments (…) and issued a joint ministerial decision to start it in 2019, while we have provided 500 million euros”, explained the minister.
“In 2020 we moved on to a new ministerial decision and invested 100 million euros,” said Georgiadis, adding: “And we have the political will to move forward with a more stable three-year agreement. between us, if all goes well. with the Stimulus Fund. “
However, he clarified that “the recovery of investments is not tax relief, which is why there are no state subsidies”.
This will be done in exchange for new jobs, research and development in Greece, he said, and a successful example is Pfizer’s investment in Thessaloniki, which the company has chosen from six other countries. .
READ MORE: “Thessaloniki may become Greece’s Silicon Valley,” says Pfizer director.